Arcutis (ARQT) Announces Long-Term Phase 3 Data for ZORYVE Cream in Children [Yahoo! Finance]
Arcutis Biotherapeutics, Inc. - Common stock (ARQT)
Company Research
Source: Yahoo! Finance
Arcutis Biotherapeutics Inc. (NASDAQ: ARQT ) is one of the best growth stocks to buy right now . On March 10, Arcutis Biotherapeutics announced the publication of long-term Phase 3 data regarding ZORYVE (roflumilast) cream 0.05% for children aged 2 to 5 with mild-to-moderate atopic dermatitis. The INTEGUMENT-OLE study, which followed patients for up to 52 weeks, showed that the once-daily nonsteroidal treatment is safe and well-tolerated, with efficacy that consistently improved over the course of the year. These findings supported the FDA approval of the 0.05% strength in October 2025, providing a durable option for a pediatric population that often faces limited long-term therapy choices. The study results showed that 63.1% of children who completed 56 weeks of treatment achieved ‘Clear' or ‘Almost Clear' skin, and over 70% reached a 75% reduction in their Eczema Area and Severity Index score. Arcutis (ARQT) Announces Long-Term Phase 3 Data for ZORYVE Cream in Children Copyri
Show less
Read more
Impact Snapshot
Event Time:
ARQT
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
ARQT alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
ARQT alerts
High impacting Arcutis Biotherapeutics, Inc. - Common stock news events
Weekly update
A roundup of the hottest topics
ARQT
News
- Arcutis Biotherapeutics (ARQT) Valuation Check After New Pediatric ZORYVE Phase 3 Extension Data [Yahoo! Finance]Yahoo! Finance
- Arcutis to Present New Clinical Data in a Late-Breaking Podium Presentation and Scientific Posters at the 2026 American Academy of Dermatology Annual MeetingGlobeNewswire
- Arcutis Announces Publication of Positive Long-Term Safety and Efficacy Data with ZORYVE® (roflumilast) Cream 0.05% for Treatment of Mild-to-Moderate Atopic Dermatitis in Children Ages 2–5 in Pediatric Dermatology [Yahoo! Finance]Yahoo! Finance
- Arcutis Announces Publication of Positive Long-Term Safety and Efficacy Data with ZORYVE® (roflumilast) Cream 0.05% for Treatment of Mild-to-Moderate Atopic Dermatitis in Children Ages 2–5 in Pediatric DermatologyGlobeNewswire
- Guggenheim Raises Its Price Target on Arcutis Biotherapeutics, Inc. (ARQT) to $35 and Maintains a Buy Rating [Yahoo! Finance]Yahoo! Finance
ARQT
Earnings
- 2/25/26 - Beat
ARQT
Sec Filings
- 3/4/26 - Form 4
- 3/4/26 - Form 4
- 3/3/26 - Form 4
- ARQT's page on the SEC website